おすすめの製品
由来生物
mouse
品質水準
100
500
結合体
unconjugated
抗体製品の状態
culture supernatant
抗体製品タイプ
primary antibodies
クローン
11, monoclonal
詳細
For In Vitro Diagnostic Use in Select Regions (See Chart)
形状
buffered aqueous solution
化学種の反応性
human
包装
vial of 0.1 mL concentrate (415M-14)
vial of 0.5 mL concentrate (415M-15)
bottle of 1.0 mL predilute (415M-17)
vial of 1.0 mL concentrate (415M-16)
bottle of 7.0 mL predilute (415M-18)
メーカー/製品名
Cell Marque™
テクニック
immunohistochemistry (formalin-fixed, paraffin-embedded sections): 1:25-1:100
アイソタイプ
IgG1
コントロール
breast carcinoma, prostate adenocarcinoma, tonsil
輸送温度
wet ice
保管温度
2-8°C
視覚化
nuclear
遺伝子情報
human ... EZH2(2146)
詳細
Enhancer of zeste homolog 2 (EZH2) is the catalytic subunit of polycomb repressive complex 2 (PRC2). It generates a methylation epigenetic mark at lysine 27 residue of histone H3 (H3K27me3) in order to silence gene expression. EZH2 target genes are involved in a variety of biological processes such as stem cell pluripotency, cell proliferation, and oncogenic transformation. EZH2 is frequently overexpressed in many cancer types. Hyperactivation of EZH2, either by overexpression or mutations, is found in a variety of malignancies including prostate, breast, uterine, gastric, and renal cell cancers in addition to melanoma. EZH2 overexpression has been reported in non-small cell lung cancers and lymphoma.The EZH2 protein is rarely detected in normal breast duct epithelium and in normal and hyperplastic lymph node. EZH2 is usually expressed in follicular centers, but not in mantle zones, follicular and interfollicular T cells, plasma cells or NK/T cells. However, its expression can be seen in most B-cell and T-cell lymphomas, although only in 20% (1/5) of small lymphocytic lymphoma and 14% (1/7) of plasma cell myeloma. Plasmacytoma, lymphoplasmacytic lymphoma, and MALT lymphoma have not been shown to express this protein. Recent studies also have demonstrated EZH2 is aberrantly over-expressed in pediatric rhabdomyosarcoma, independent of the histological subtypes. In summary, EZH2 correlates with tumor proliferation and may be used in an antibody panel to differentiate proliferative/aggressive lymphoma variants from indolent ones and normal resting cell populations
品質
IVD | IVD | IVD | RUO |
関連事項
EZH2 Positive Control Slides, Product No. 415S, are available for immunohistochemistry (formalin-fixed, paraffin-embedded sections).
物理的形状
Solution in Tris Buffer, pH 7.3-7.7, with 1% BSA and <0.1% Sodium Azide
調製ノート
Download the IFU specific to your product lot and formatNote: This requires a keycode which can be found on your packaging or product label.
その他情報
For Technical Service please contact: 800-665-7284 or email: service@cellmarque.com
法的情報
Cell Marque is a trademark of Merck KGaA, Darmstadt, Germany
適切な製品が見つかりませんか。
製品選択ツール.をお試しください
試験成績書(COA)
製品のロット番号・バッチ番号を入力して、試験成績書(COA) を検索できます。ロット番号・バッチ番号は、製品ラベルに「Lot」または「Batch」に続いて記載されています。
Acta pharmacologica Sinica, 35(2), 161-174 (2013-12-24)
EZH2 is the catalytic subunit of the polycomb repressive complex 2 (PRC2), which is a highly conserved histone methyltransferase that methylates lysine 27 of histone 3. Overexpression of EZH2 has been found in a wide range of cancers, including those
Virchows Archiv : an international journal of pathology, 463(5), 697-711 (2013-08-21)
Polycomb group (PcG) proteins are important for the regulation of hematopoiesis by regulating chromatin compaction and silencing genes related to differentiation and cell cycle. Overexpression of enhancer of zeste homologue 2 (Ezh2) and Bmi-1/PCGF4 has been implicated in solid organ
Nature, 419(6907), 624-629 (2002-10-11)
Prostate cancer is a leading cause of cancer-related death in males and is second only to lung cancer. Although effective surgical and radiation treatments exist for clinically localized prostate cancer, metastatic prostate cancer remains essentially incurable. Here we show, through
BMC medicine, 9, 63-63 (2011-05-26)
Soft tissue sarcomas of childhood are a group of heterogeneous tumors thought to be derived from mesenchymal stem cells. Surgical resection is effective only in about 50% of cases and resistance to conventional chemotherapy is often responsible for treatment failure.
ライフサイエンス、有機合成、材料科学、クロマトグラフィー、分析など、あらゆる分野の研究に経験のあるメンバーがおります。.
製品に関するお問い合わせはこちら(テクニカルサービス)